372 related articles for article (PubMed ID: 26741346)
1. SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.
Balgkouranidou I; Chimonidou M; Milaki G; Tsaroucha E; Kakolyris S; Georgoulias V; Lianidou E
Clin Chem Lab Med; 2016 Aug; 54(8):1385-93. PubMed ID: 26741346
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.
Balgkouranidou I; Chimonidou M; Milaki G; Tsarouxa EG; Kakolyris S; Welch DR; Georgoulias V; Lianidou ES
Br J Cancer; 2014 Apr; 110(8):2054-62. PubMed ID: 24642624
[TBL] [Abstract][Full Text] [Related]
3. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival.
Balgkouranidou I; Karayiannakis A; Matthaios D; Bolanaki H; Tripsianis G; Tentes AA; Lianidou E; Chatzaki E; Fiska A; Lambropoulou M; Kolios G; Kakolyris S
Clin Chem Lab Med; 2013 Jul; 51(7):1505-10. PubMed ID: 23403728
[TBL] [Abstract][Full Text] [Related]
4. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer.
Chimonidou M; Strati A; Malamos N; Georgoulias V; Lianidou ES
Clin Chem; 2013 Jan; 59(1):270-9. PubMed ID: 23136251
[TBL] [Abstract][Full Text] [Related]
5. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
[TBL] [Abstract][Full Text] [Related]
6. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
[TBL] [Abstract][Full Text] [Related]
7. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.
Fu D; Ren C; Tan H; Wei J; Zhu Y; He C; Shao W; Zhang J
Medicine (Baltimore); 2015 Mar; 94(11):e637. PubMed ID: 25789956
[TBL] [Abstract][Full Text] [Related]
8. A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples.
Mastoraki S; Chimonidou M; Dimitrakopoulos L; Kounelis S; Malamos N; Georgoulias V; Lianidou E
Clin Chim Acta; 2015 Apr; 444():303-9. PubMed ID: 25727515
[TBL] [Abstract][Full Text] [Related]
9. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
Zhang Y; Miao Y; Yi J; Wang R; Chen L
Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
[TBL] [Abstract][Full Text] [Related]
10. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
12. Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules.
Chen C; Huang X; Yin W; Peng M; Wu F; Wu X; Tang J; Chen M; Wang X; Hulbert A; Brock MV; Liu W; Herman JG; Yu F
Clin Epigenetics; 2020 Mar; 12(1):39. PubMed ID: 32138766
[TBL] [Abstract][Full Text] [Related]
13. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients.
An Q; Liu Y; Gao Y; Huang J; Fong X; Li L; Zhang D; Cheng S
Cancer Lett; 2002 Dec; 188(1-2):109-14. PubMed ID: 12406555
[TBL] [Abstract][Full Text] [Related]
14. Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer.
Liu B; Ricarte Filho J; Mallisetty A; Villani C; Kottorou A; Rodgers K; Chen C; Ito T; Holmes K; Gastala N; Valyi-Nagy K; David O; Gaba RC; Ascoli C; Pasquinelli M; Feldman LE; Massad MG; Wang TH; Jusue-Torres I; Benedetti E; Winn RA; Brock MV; Herman JG; Hulbert A
Clin Cancer Res; 2020 Aug; 26(16):4339-4348. PubMed ID: 32430478
[TBL] [Abstract][Full Text] [Related]
15. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122
[TBL] [Abstract][Full Text] [Related]
16. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC).
Feng H; Zhang Z; Qing X; Wang X; Liang C; Liu D
Exp Mol Pathol; 2016 Feb; 100(1):109-13. PubMed ID: 26681652
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients.
Karamitrousis EI; Balgkouranidou I; Xenidis N; Amarantidis K; Biziota E; Koukaki T; Trypsianis G; Karayiannakis A; Bolanaki H; Kolios G; Lianidou E; Kakolyris S
Technol Cancer Res Treat; 2021; 20():1533033820973279. PubMed ID: 33928818
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
20. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.
Nie K; Jia Y; Zhang X
Tumour Biol; 2015 Jan; 36(1):7-19. PubMed ID: 25352029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
